Clinuvel Pharmaceuticals (CUV)

Download button icon Download

Clinuvel Pharmaceuticals (CUV): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

DETREND PRICE OSCILLATOR


Last Signal:

BEARISH


Trading: SELL @ $19.19
Signal Strength: STRONG
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.


Clinuvel Pharmaceuticals (ASX:CUV) currently has a confirmed downtrend. Price is currently below the displaced moving average for CUV Currently, the return on DPO20 is -8.5%.



The Detrended Price Oscillator (DPO) is an indicator designed to remove trend from price and make it easier to identify cycles. DPO does not extend to the last date because it is based on a displaced moving average. However alignment with the most recent is not an issue because DPO is not a momentum oscillator. Instead DPO is used to identify cycle’s highs/lows and estimate cycle length.

Calculation: Detrended Price Oscillator (DPO):
1) Price (X/2 + 1) periods ago minus X-period simple moving average.
Where X is the number of periods;


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Detrended Price Oscillator

Download button icon Download
Company Close Change (%) Volume Value Signal
BKI Brickworks Investment 1.51 -0.3 301,820 0 BEARISH CROSSOVER
PMC Platinum Capital 1.81 -0.8 68,626 -0.01 BEARISH CROSSOVER
MVP Medical Developments 4.8 -1 46,852 -0.02 BEARISH CROSSOVER
COE Cooper Energy 0.47 -1.1 2,544,656 0 BEARISH CROSSOVER
QVE QV Equities 1.11 -1.3 237,590 0 BEARISH CROSSOVER
WAF West African Resources 0.28 -1.8 154,587 0 BEARISH CROSSOVER
GOR Gold Road Resources 0.69 -2.1 1,151,814 -0.01 BEARISH CROSSOVER
GGG Greenland Minerals 0.08 -2.3 627,895 0 BEARISH CROSSOVER
NEA Nearmap 1.5 -2.3 1,111,803 -0.01 BEARISH CROSSOVER
EAI Ellerston Asian Investment 1.01 -2.4 35,000 -0.01 BEARISH CROSSOVER
back to top